Celltrion Keeps Pace With Ustekinumab Discounts As It Launches US Stelara Rival

Steqeyma Version Introduced With WAC 85% Lower Than $10bn Brand

 
• By Dave Wallace

Celltrion has become the latest firm to enter the competitive US market for Stelara biosimilars, revealing details of its Steqeyma launch.

Discounts are high for US Stelara rivals (Shutterstock)

More from Biosimilars

More from Earnings